Recruiting

Testing an oral carbon monoxide treatment for sickle cell disease

Plain-English translation of NCT06144749 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing , an oral liquid medication containing carbon monoxide, to see if it is safe and effective for people with sickle cell disease. Researchers want to understand how the medication works in the body and whether it can help reduce complications from sickle cell disease. The medication will be taken daily for 14 days, and researchers will carefully monitor participants' health throughout the trial.

Sickle cell disease causes severe pain and serious health complications that current treatments don't always prevent. This medication is being explored as a new treatment option to see if it can help protect the body and improve outcomes for people living with this condition.

Do you qualify?

You likely qualify if…

you are between 14 and 55 years old
you have been diagnosed with sickle cell disease (specifically HbSS or Hb-Sβ⁰ type)
you have had no more than 10 vaso-occlusive crises (severe pain episodes) in the past two years
you have experienced at least one serious complication such as acute chest syndrome, stroke, priapism, bone damage, or splenic sequestration
you do not smoke or use vaping products (tobacco or marijuana) and have not used them for at least 3 months
you are willing to use effective birth control for the duration of the study and 30 days after

You likely don't qualify if…

you have a type of sickle cell disease other than HbSS or Hb-Sβ⁰
you have current evidence of heart disease or abnormal heart function
you are pregnant or breastfeeding
you have tested positive for hepatitis B, hepatitis C, or HIV
you have significant liver or kidney disease

What participation looks like

If you qualify, you will take the medication by mouth once daily for 14 days. During this time, you will have multiple study visits where the research team will check your vital signs, take blood samples to monitor your health and measure how your body processes the medication, and ask about any side effects you may be experiencing. The entire study will take a few weeks from screening to final follow-up.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(2 sites)

Panama

Cevaxin - The Panama Clinic, Panama City

Hospital Pacífica Salud, Panama City